Berlin, Germany, and U.S.A. – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, announced today that it has entered into a joint commercialization agreement with Polymedco Inc., a leading provider of colorectal cancer tests in North America. Both companies will jointly commercialize Epi proColon®, Epigenomics’ blood-based test for colorectal cancer (CRC) screening, in North America.
{iframe}http://www.epigenomics.com/en/news-investors/news-media/press-releases/article/epigenomics-und-polymedco-unterzeichnen-kommerzialisierungsvereinbarung-fuer-epi-procolonR-fuer-den-no.html?utm_source=+BioMaryland+Update+10-4-13&utm_campaign=Update+-9%2F17&utm_medium=email{/iframe}